Mental & Behavioral Health
Digital Breakthrough Targets Schizophrenia's Most Stubborn Symptoms as FDA Clears First Smartphone-Based Treatment
Click Therapeutics' Motivista becomes the first FDA-cleared prescription digital therapeutic specifically designed to treat negative symptoms affecting 60% of schizophrenia patients.
Health AI Central Editorial Team·October 13, 2026
Mental & Behavioral Health
Digital Therapy Breaks New Ground as First FDA-Authorized Treatment for Schizophrenia's Most Debilitating Symptoms
Click Therapeutics' smartphone-delivered intervention targets negative symptoms that have long eluded effective treatment, demonstrating 62% improvement over control in pivotal trial.
Health AI Central Editorial Team·October 10, 2026